id
stringlengths 11
11
| tags
stringlengths 10
777
| text
stringlengths 2
1.5k
| dataset_num
int64 1
3
| tokens
list | ner_tags
list |
|---|---|---|---|---|---|
NCT02734771
|
24:27:chronic_disease
|
Patient is known to be HIV positive (test result not required for enrollment)
| 1
|
[
"Patient",
"is",
"known",
"to",
"be",
"HIV",
"positive",
"(",
"test",
"result",
"not",
"required",
"for",
"enrollment",
")"
] |
[
0,
0,
0,
0,
0,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02115295
|
74:86:treatment
|
Patient with documented hypersensitivity to any of the components of the chemotherapy program
| 1
|
[
"Patient",
"with",
"documented",
"hypersensitivity",
"to",
"any",
"of",
"the",
"components",
"of",
"the",
"chemotherapy",
"program"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0
] |
NCT02587962
|
1:19:treatment,21:52:treatment,56:68:treatment,,107:117:treatment
|
Prior chemotherapy, targeted small molecule therapy or radiotherapy within 2 weeks prior to first dose of study drug
| 1
|
[
"Prior",
"chemotherapy",
",",
"targeted",
"small",
"molecule",
"therapy",
"or",
"radiotherapy",
"within",
"2",
"weeks",
"prior",
"to",
"first",
"dose",
"of",
"study",
"drug"
] |
[
1,
1,
0,
1,
1,
1,
1,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0,
1,
1
] |
NCT02159703
|
7:19:treatment,
|
Prior chemotherapy within the past 5 years
| 1
|
[
"Prior",
"chemotherapy",
"within",
"the",
"past",
"5",
"years"
] |
[
0,
1,
0,
0,
0,
0,
0
] |
NCT01993810
|
16:26:cancer,
|
Prior invasive malignancy unless disease free for a minimum of 3 years
| 1
|
[
"Prior",
"invasive",
"malignancy",
"unless",
"disease",
"free",
"for",
"a",
"minimum",
"of",
"3",
"years"
] |
[
0,
0,
3,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02436408
|
,,48:57:treatment,
|
Male patients must agree to use condoms during treatment and for 3 months after last dose
| 1
|
[
"Male",
"patients",
"must",
"agree",
"to",
"use",
"condoms",
"during",
"treatment",
"and",
"for",
"3",
"months",
"after",
"last",
"dose"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0,
0,
0
] |
NCT02107703
|
14:30:cancer,47:65:treatment,69:76:treatment,80:98:cancer
|
Have locally advanced disease not amenable to curative treatment by surgery or metastatic disease
| 1
|
[
"Have",
"locally",
"advanced",
"disease",
"not",
"amenable",
"to",
"curative",
"treatment",
"by",
"surgery",
"or",
"metastatic",
"disease"
] |
[
0,
0,
3,
3,
0,
0,
0,
1,
1,
0,
1,
0,
3,
3
] |
NCT01817751
|
12:41:treatment
|
Current or prior valproic acid treatment is allowed
| 1
|
[
"Current",
"or",
"prior",
"valproic",
"acid",
"treatment",
"is",
"allowed"
] |
[
0,
0,
1,
1,
1,
1,
0,
0
] |
NCT01880567
|
14:26:chronic_disease,41:58:chronic_disease,67:102:chronic_disease,104:120:chronic_disease,131:140:treatment,146:166:treatment,168:177:treatment,181:198:treatment,200:217:chronic_disease,222:241:chronic_disease
|
uncontrolled hypertension, uncontrolled diabetes mellitus, active/symptomatic coronary artery disease, active infection requiring treatment with systemic antibiotics, antiviral or antifungal agents, active hemorrhage, or psychiatric illness
| 1
|
[
"uncontrolled",
"hypertension",
",",
"uncontrolled",
"diabetes",
"mellitus",
",",
"active/symptomatic",
"coronary",
"artery",
"disease",
",",
"active",
"infection",
"requiring",
"treatment",
"with",
"systemic",
"antibiotics",
",",
"antiviral",
"or",
"antifungal",
"agents",
",",
"active",
"hemorrhage",
",",
"or",
"psychiatric",
"illness"
] |
[
0,
2,
0,
0,
2,
2,
0,
2,
2,
2,
2,
0,
0,
0,
0,
1,
0,
1,
1,
0,
1,
0,
1,
1,
0,
0,
0,
0,
0,
2,
2
] |
NCT02159703
|
7:19:treatment,
|
Prior chemotherapy within the past 5 years
| 1
|
[
"Prior",
"chemotherapy",
"within",
"the",
"past",
"5",
"years"
] |
[
0,
1,
0,
0,
0,
0,
0
] |
NCT02323191
|
14:33:treatment,45:57:treatment,61:77:treatment,
|
Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatment, with the exceptions provided in the protocol
| 1
|
[
"Any",
"approved",
"anti-cancer",
"therapy",
",",
"including",
"chemotherapy",
"or",
"hormonal",
"therapy",
",",
"within",
"3",
"weeks",
"prior",
"to",
"initiation",
"of",
"study",
"treatment",
",",
"with",
"the",
"exceptions",
"provided",
"in",
"the",
"protocol"
] |
[
0,
0,
1,
1,
0,
0,
1,
0,
1,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02120222
|
13:47:chronic_disease
|
Known to be human immunodeficiency virus (HIV) seropositive
| 1
|
[
"Known",
"to",
"be",
"human",
"immunodeficiency",
"virus",
"(",
"HIV",
")",
"seropositive"
] |
[
0,
0,
0,
2,
2,
2,
2,
0,
0,
0
] |
NCT01597518
|
1:14:treatment
|
Thiabendazole
| 1
|
[
"Thiabendazole"
] |
[
1
] |
NCT02100891
|
,,,108:117:treatment
|
Fertile males who are unwilling to use contraceptive techniques during and for the twelve months following treatment
| 1
|
[
"Fertile",
"males",
"who",
"are",
"unwilling",
"to",
"use",
"contraceptive",
"techniques",
"during",
"and",
"for",
"the",
"twelve",
"months",
"following",
"treatment"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1
] |
NCT03112759
|
62:82:chronic_disease
|
Participating in another clinical trial for the treatment of chronic pancreatitis at the time of screening
| 1
|
[
"Participating",
"in",
"another",
"clinical",
"trial",
"for",
"the",
"treatment",
"of",
"chronic",
"pancreatitis",
"at",
"the",
"time",
"of",
"screening"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
2,
2,
0,
0,
0,
0,
0
] |
NCT02091999
|
9:34:treatment
|
Routine antimicrobial prophylaxis is permitted
| 1
|
[
"Routine",
"antimicrobial",
"prophylaxis",
"is",
"permitted"
] |
[
0,
1,
1,
0,
0
] |
NCT02588612
|
1:17:chronic_disease,23:57:chronic_disease,53:56:chronic_disease,59:82:chronic_disease,84:107:chronic_disease,111:149:chronic_disease,211:239:chronic_disease,289:317:chronic_disease,369:381:treatment,646:657:chronic_disease
|
Active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) or human T-cell lymphotropic virus (HTLV) as minimally defined below: a) Positive serology for HIV. b) Active hepatitis B infection as determined by hepatitis B surface antigen. c) Active hepatitis C infection as determined by hepatitis C RNA; A subject who is HCV antibody positive will be screened for HCV ribonucleic acid (RNA) by any reverse transcriptase (RT) polymerase chain reaction (PCR) or bDNA assay. If HCV antibody is positive, eligibility will be determined based on a negative screening RNA value. d) Positive serology for HTLV 1 or 2
| 1
|
[
"Active",
"infection",
"with",
"human",
"immunodeficiency",
"virus",
"(",
"HIV",
")",
",",
"hepatitis",
"B",
"virus",
"(",
"HBV",
")",
",",
"hepatitis",
"C",
"virus",
"(",
"HCV",
")",
"or",
"human",
"T-cell",
"lymphotropic",
"virus",
"(",
"HTLV",
")",
"as",
"minimally",
"defined",
"below",
":",
"a",
")",
"Positive",
"serology",
"for",
"HIV",
".",
"b",
")",
"Active",
"hepatitis",
"B",
"infection",
"as",
"determined",
"by",
"hepatitis",
"B",
"surface",
"antigen",
".",
"c",
")",
"Active",
"hepatitis",
"C",
"infection",
"as",
"determined",
"by",
"hepatitis",
"C",
"RNA",
";",
"A",
"subject",
"who",
"is",
"HCV",
"antibody",
"positive",
"will",
"be",
"screened",
"for",
"HCV",
"ribonucleic",
"acid",
"(",
"RNA",
")",
"by",
"any",
"reverse",
"transcriptase",
"(",
"RT",
")",
"polymerase",
"chain",
"reaction",
"(",
"PCR",
")",
"or",
"bDNA",
"assay",
".",
"If",
"HCV",
"antibody",
"is",
"positive",
",",
"eligibility",
"will",
"be",
"determined",
"based",
"on",
"a",
"negative",
"screening",
"RNA",
"value",
".",
"d",
")",
"Positive",
"serology",
"for",
"HTLV",
"1",
"or",
"2"
] |
[
2,
2,
2,
2,
2,
2,
2,
2,
0,
0,
2,
2,
2,
2,
0,
0,
0,
0,
0,
0,
0,
1,
1,
0,
0,
0,
0,
0,
0,
2,
2,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT01399476
|
1:43:treatment
|
Previous mediastinal or esophageal surgery
| 1
|
[
"Previous",
"mediastinal",
"or",
"esophageal",
"surgery"
] |
[
1,
1,
1,
1,
1
] |
NCT00713492
|
37:52:chronic_disease,64:67:chronic_disease,69:83:chronic_disease,85:96:chronic_disease,98:114:chronic_disease,116:123:chronic_disease,125:130:chronic_disease,132:141:chronic_disease,146:168:chronic_disease
|
Current or prior history of serious medical illness, including CNS, cardiovascular, respiratory, gastrointestinal, hepatic, renal, endocrine, or reproductive disorders
| 1
|
[
"Current",
"or",
"prior",
"history",
"of",
"serious",
"medical",
"illness",
",",
"including",
"CNS",
",",
"cardiovascular",
",",
"respiratory",
",",
"gastrointestinal",
",",
"hepatic",
",",
"renal",
",",
"endocrine",
",",
"or",
"reproductive",
"disorders"
] |
[
0,
0,
0,
0,
0,
0,
2,
2,
0,
0,
2,
0,
2,
0,
2,
0,
2,
0,
2,
0,
2,
0,
2,
0,
0,
2,
2
] |
NCT02675114
|
16:43:chronic_disease,
|
Evidence of an acute myocardial infarction ≤ 1 month (30 days) before randomization
| 1
|
[
"Evidence",
"of",
"an",
"acute",
"myocardial",
"infarction",
"≤",
"1",
"month",
"(",
"30",
"days",
")",
"before",
"randomization"
] |
[
0,
0,
0,
2,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT01356290
|
1:20:chronic_disease
|
Active peptic ulcer
| 1
|
[
"Active",
"peptic",
"ulcer"
] |
[
2,
2,
2
] |
NCT02425904
|
49:62:treatment
|
There is no limitation of amount or the type of prior therapy or drugs
| 1
|
[
"There",
"is",
"no",
"limitation",
"of",
"amount",
"or",
"the",
"type",
"of",
"prior",
"therapy",
"or",
"drugs"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
1,
0,
0
] |
NCT02498951
|
,,,100:112:treatment
|
for women, effective contraception is required to continue for >= 12 months after the last dose of obinutuzumab
| 1
|
[
"for",
"women",
",",
"effective",
"contraception",
"is",
"required",
"to",
"continue",
"for",
">",
"=",
"12",
"months",
"after",
"the",
"last",
"dose",
"of",
"obinutuzumab"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1
] |
NCT01280669
|
1:19:chronic_disease
|
Pupillary dilation inadequate for quality fundus photography in the study eye
| 1
|
[
"Pupillary",
"dilation",
"inadequate",
"for",
"quality",
"fundus",
"photography",
"in",
"the",
"study",
"eye"
] |
[
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02446457
|
39:52:treatment,90:111:treatment,125:135:treatment,148:168:treatment,,191:214:treatment
|
currently participating and receiving study therapy or has participated in a study of an investigational agent and received study drug or using an investigation device within 4 weeks of the first dose of treatment
| 1
|
[
"currently",
"participating",
"and",
"receiving",
"study",
"therapy",
"or",
"has",
"participated",
"in",
"a",
"study",
"of",
"an",
"investigational",
"agent",
"and",
"received",
"study",
"drug",
"or",
"using",
"an",
"investigation",
"device",
"within",
"4",
"weeks",
"of",
"the",
"first",
"dose",
"of",
"treatment"
] |
[
0,
0,
0,
0,
1,
1,
0,
0,
0,
0,
0,
0,
0,
0,
1,
1,
0,
0,
0,
0,
0,
0,
0,
1,
1,
0,
0,
0,
0,
0,
1,
1,
1,
1
] |
NCT01912612
|
39:52:cancer
|
Pain that developed or worsened since breast cancer diagnosis and is not due to identifiable traumatic event or fracture
| 1
|
[
"Pain",
"that",
"developed",
"or",
"worsened",
"since",
"breast",
"cancer",
"diagnosis",
"and",
"is",
"not",
"due",
"to",
"identifiable",
"traumatic",
"event",
"or",
"fracture"
] |
[
0,
0,
0,
0,
0,
0,
3,
3,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02132598
|
1:26:chronic_disease,27:32:chronic_disease,,93:102:treatment
|
Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment
| 1
|
[
"Serious",
"non-healing",
"wound/ulcer/bone",
"fracture",
"within",
"28",
"days",
"before",
"the",
"first",
"dose",
"of",
"study",
"treatment"
] |
[
2,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1
] |
NCT01716806
|
20:30:cancer,
|
History of another malignancy within 1 year before first dose of study drug (Parts E and F only)
| 1
|
[
"History",
"of",
"another",
"malignancy",
"within",
"1",
"year",
"before",
"first",
"dose",
"of",
"study",
"drug",
"(",
"Parts",
"E",
"and",
"F",
"only",
")"
] |
[
0,
0,
0,
3,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02213289
|
4:43:treatment
|
No prior treatment with any targeted agent
| 1
|
[
"No",
"prior",
"treatment",
"with",
"any",
"targeted",
"agent"
] |
[
0,
1,
1,
1,
1,
1,
1
] |
NCT01532687
|
32:41:treatment
|
must be willing to comply with treatment and follow-up
| 1
|
[
"must",
"be",
"willing",
"to",
"comply",
"with",
"treatment",
"and",
"follow-up"
] |
[
0,
0,
0,
0,
0,
0,
1,
0,
0
] |
NCT02146924
|
70:85:treatment
|
Research participant has a released cryopreserved T cell product for T cell infusion on approximately day 0
| 1
|
[
"Research",
"participant",
"has",
"a",
"released",
"cryopreserved",
"T",
"cell",
"product",
"for",
"T",
"cell",
"infusion",
"on",
"approximately",
"day",
"0"
] |
[
0,
0,
0,
0,
0,
0,
1,
1,
1,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02006069
|
1:14:chronic_disease
|
Persistent AF at the time of enrollment
| 1
|
[
"Persistent",
"AF",
"at",
"the",
"time",
"of",
"enrollment"
] |
[
2,
2,
0,
0,
0,
0,
0
] |
NCT03105700
|
1:9:treatment
|
caffeine
| 1
|
[
"caffeine"
] |
[
1
] |
NCT02408861
|
16:25:treatment,30:40:treatment,118:136:treatment,172:183:treatment,,,,,,,,489:509:treatment
|
The effects of nivolumab and ipilimumab on the developing human fetus are unknown; for this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of childbearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; WOCBP should use an adequate method to avoid pregnancy for 6 months after the last dose of investigational drug
| 1
|
[
"The",
"effects",
"of",
"nivolumab",
"and",
"ipilimumab",
"on",
"the",
"developing",
"human",
"fetus",
"are",
"unknown",
";",
"for",
"this",
"reason",
"and",
"because",
"other",
"therapeutic",
"agents",
"used",
"in",
"this",
"trial",
"are",
"known",
"to",
"be",
"teratogenic",
",",
"women",
"of",
"childbearing",
"potential",
"(",
"WOCBP",
")",
"and",
"men",
"must",
"agree",
"to",
"use",
"adequate",
"contraception",
"(",
"hormonal",
"or",
"barrier",
"method",
"of",
"birth",
"control",
";",
"abstinence",
")",
"prior",
"to",
"study",
"entry",
"and",
"for",
"the",
"duration",
"of",
"study",
"participation",
";",
"WOCBP",
"should",
"use",
"an",
"adequate",
"method",
"to",
"avoid",
"pregnancy",
"for",
"6",
"months",
"after",
"the",
"last",
"dose",
"of",
"investigational",
"drug"
] |
[
0,
0,
0,
1,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
1,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
1
] |
NCT03125902
|
10:44:chronic_disease
|
Negative human immunodeficiency virus (HIV) test at screening
| 1
|
[
"Negative",
"human",
"immunodeficiency",
"virus",
"(",
"HIV",
")",
"test",
"at",
"screening"
] |
[
0,
2,
2,
2,
2,
0,
0,
0,
0,
0
] |
NCT00540761
|
8:35:chronic_disease
|
severe peripheral vascular disease
| 1
|
[
"severe",
"peripheral",
"vascular",
"disease"
] |
[
0,
2,
2,
2
] |
NCT01415882
|
1:15:treatment,
|
Anthracyclines =< 14 days prior to registration
| 1
|
[
"Anthracyclines",
"=",
"<",
"14",
"days",
"prior",
"to",
"registration"
] |
[
1,
0,
0,
0,
0,
0,
0,
0
] |
NCT02515110
|
138:150:cancer
|
Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) testing performed on the primary breast tumor
| 1
|
[
"Estrogen",
"receptor",
"(",
"ER",
")",
",",
"progesterone",
"receptor",
"(",
"PR",
")",
",",
"and",
"human",
"epidermal",
"growth",
"factor",
"receptor",
"2",
"(",
"HER2",
")",
"testing",
"performed",
"on",
"the",
"primary",
"breast",
"tumor"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
3
] |
NCT02140554
|
22:32:cancer,36:61:chronic_disease
|
Any prior or current malignancy or immunodeficiency disorder
| 1
|
[
"Any",
"prior",
"or",
"current",
"malignancy",
"or",
"immunodeficiency",
"disorder"
] |
[
0,
0,
0,
0,
3,
0,
2,
2
] |
NCT02041936
|
59:81:treatment,
|
Receive non-conventional fractionation schedules, such as stereotactic radiation (5 fractions or less)
| 1
|
[
"Receive",
"non-conventional",
"fractionation",
"schedules",
",",
"such",
"as",
"stereotactic",
"radiation",
"(",
"5",
"fractions",
"or",
"less",
")"
] |
[
0,
0,
0,
0,
0,
0,
0,
1,
1,
0,
0,
0,
0,
0,
0
] |
NCT02094625
|
1:37:chronic_disease,154:173:chronic_disease,195:205:treatment,223:238:treatment,
|
Moderate or Severe Persistent Asthma as defined by the latest recommendations from the National Heart Lung and Blood Institute definition includes daily asthma exacerbation with need for rescue medication) or an overnight hospitalization for asthma exacerbation within the previous 28 days
| 1
|
[
"Moderate",
"or",
"Severe",
"Persistent",
"Asthma",
"as",
"defined",
"by",
"the",
"latest",
"recommendations",
"from",
"the",
"National",
"Heart",
"Lung",
"and",
"Blood",
"Institute",
"definition",
"includes",
"daily",
"asthma",
"exacerbation",
"with",
"need",
"for",
"rescue",
"medication",
")",
"or",
"an",
"overnight",
"hospitalization",
"for",
"asthma",
"exacerbation",
"within",
"the",
"previous",
"28",
"days"
] |
[
2,
2,
2,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
2,
2,
0,
0,
0,
0,
1,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02863809
|
1:29:chronic_disease
|
systemic lupus erythematosis
| 1
|
[
"systemic",
"lupus",
"erythematosis"
] |
[
2,
2,
2
] |
NCT02255383
|
18:29:treatment
|
Stable, painless arthrodesis in a satisfactory functional position
| 1
|
[
"Stable",
",",
"painless",
"arthrodesis",
"in",
"a",
"satisfactory",
"functional",
"position"
] |
[
0,
0,
0,
1,
0,
0,
0,
0,
0
] |
NCT02276456
|
23:54:treatment
|
Patients treated with coronary artery bypass grafting will be excluded for the purposes of this trial to avoid conflicts with usual post-operative management
| 1
|
[
"Patients",
"treated",
"with",
"coronary",
"artery",
"bypass",
"grafting",
"will",
"be",
"excluded",
"for",
"the",
"purposes",
"of",
"this",
"trial",
"to",
"avoid",
"conflicts",
"with",
"usual",
"post-operative",
"management"
] |
[
0,
0,
0,
1,
1,
1,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02926248
|
20:33:treatment
|
Patients requiring bilateral MUA
| 1
|
[
"Patients",
"requiring",
"bilateral",
"MUA"
] |
[
0,
0,
1,
1
] |
NCT02013336
|
27:40:treatment
|
Disease progression after prior therapy in locally advanced or metastatic setting
| 1
|
[
"Disease",
"progression",
"after",
"prior",
"therapy",
"in",
"locally",
"advanced",
"or",
"metastatic",
"setting"
] |
[
0,
0,
0,
1,
1,
0,
0,
0,
0,
0,
0
] |
NCT02101034
|
,49:62:treatment
|
Minimum of 14 days elapsed since the end of any prior therapy
| 1
|
[
"Minimum",
"of",
"14",
"days",
"elapsed",
"since",
"the",
"end",
"of",
"any",
"prior",
"therapy"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
1
] |
NCT03008070
|
22:34:treatment
|
Contra-indication to liver biopsy
| 1
|
[
"Contra-indication",
"to",
"liver",
"biopsy"
] |
[
0,
0,
1,
1
] |
NCT02504489
|
1:9:treatment,13:37:treatment,45:60:treatment,101:123:treatment
|
Adjuvant or neoadjuvant chemotherapy and/or chemo-radiation for early stage disease do not count as prior systemic therapy
| 1
|
[
"Adjuvant",
"or",
"neoadjuvant",
"chemotherapy",
"and/or",
"chemo-radiation",
"for",
"early",
"stage",
"disease",
"do",
"not",
"count",
"as",
"prior",
"systemic",
"therapy"
] |
[
1,
0,
1,
1,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0,
1,
1,
1
] |
NCT02519322
|
,,,,166:175:treatment
|
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.5 X upper limit of normal (ULN) (within 28 days of first study treatment)
| 1
|
[
"Prothrombin",
"time",
"(",
"PT",
")",
"/international",
"normalized",
"ratio",
"(",
"INR",
")",
"and",
"partial",
"thromboplastin",
"time",
"(",
"PTT",
")",
"=",
"<",
"1.5",
"X",
"upper",
"limit",
"of",
"normal",
"(",
"ULN",
")",
"(",
"within",
"28",
"days",
"of",
"first",
"study",
"treatment",
")"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0
] |
NCT02095184
|
21:34:cancer,,,,
|
Unresected operable breast cancer stage I-III with primary tumor ≥ 2.0 cm
| 1
|
[
"Unresected",
"operable",
"breast",
"cancer",
"stage",
"I-III",
"with",
"primary",
"tumor",
"≥",
"2.0",
"cm"
] |
[
0,
0,
3,
3,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT03132636
|
19:46:treatment
|
Having received a solid organ transplantation
| 1
|
[
"Having",
"received",
"a",
"solid",
"organ",
"transplantation"
] |
[
0,
0,
0,
1,
1,
1
] |
NCT02636530
|
15:25:treatment,
|
initiation of treatments that could impact bone metabolism (diuretics, hormones, bine anabolic agents) in the prior 6 months
| 1
|
[
"initiation",
"of",
"treatments",
"that",
"could",
"impact",
"bone",
"metabolism",
"(",
"diuretics",
",",
"hormones",
",",
"bine",
"anabolic",
"agents",
")",
"in",
"the",
"prior",
"6",
"months"
] |
[
0,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT01371630
|
36:39:cancer
|
Patients with previously untreated ALL of pre-B, Philadelphia chromosome (Ph-) negative ALL
| 1
|
[
"Patients",
"with",
"previously",
"untreated",
"ALL",
"of",
"pre-B",
",",
"Philadelphia",
"chromosome",
"(",
"Ph-",
")",
"negative",
"ALL"
] |
[
0,
0,
0,
0,
3,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02389023
|
,58:67:treatment
|
Any groin incision on index leg within 12 weeks prior to treatment initiation
| 1
|
[
"Any",
"groin",
"incision",
"on",
"index",
"leg",
"within",
"12",
"weeks",
"prior",
"to",
"treatment",
"initiation"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0
] |
NCT03081559
|
1:4:chronic_disease
|
HIV+ confirmed via antibody testing
| 1
|
[
"HIV+",
"confirmed",
"via",
"antibody",
"testing"
] |
[
2,
0,
0,
0,
0
] |
NCT02762604
|
13:21:chronic_disease,,,,
|
Presence of dementia (telephone-based memory impairment screen < 5 or Ascertain Dementia 8-item Informant Questionnaire score > 1)
| 1
|
[
"Presence",
"of",
"dementia",
"(",
"telephone-based",
"memory",
"impairment",
"screen",
"<",
"5",
"or",
"Ascertain",
"Dementia",
"8-item",
"Informant",
"Questionnaire",
"score",
">",
"1",
")"
] |
[
0,
0,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02516670
|
1:12:treatment,14:28:treatment,30:42:treatment,44:57:treatment,59:73:treatment
|
Antibiotics: clarithromycin, erythromycin, telithromycin, troleandomycin
| 1
|
[
"Antibiotics",
":",
"clarithromycin",
",",
"erythromycin",
",",
"telithromycin",
",",
"troleandomycin"
] |
[
1,
0,
1,
0,
1,
0,
1,
0,
1
] |
NCT02138617
|
18:45:chronic_disease
|
Prior history of hypertensive encephalopathy
| 1
|
[
"Prior",
"history",
"of",
"hypertensive",
"encephalopathy"
] |
[
0,
0,
0,
2,
2
] |
NCT01959425
|
1:4:treatment,51:67:treatment,69:80:chronic_disease,91:109:chronic_disease,123:154:chronic_disease,
|
OAT required for reasons not related to AF (i.e., prosthetic valve, PV stenosis, previous pulmonary embolism, presence of spontaneous echo contrast [SEC] at standard echo performed at 3-months follow-up)
| 1
|
[
"OAT",
"required",
"for",
"reasons",
"not",
"related",
"to",
"AF",
"(",
"i.e.",
",",
"prosthetic",
"valve",
",",
"PV",
"stenosis",
",",
"previous",
"pulmonary",
"embolism",
",",
"presence",
"of",
"spontaneous",
"echo",
"contrast",
"[",
"SEC",
"]",
"at",
"standard",
"echo",
"performed",
"at",
"3-months",
"follow-up",
")"
] |
[
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
1,
0,
2,
2,
0,
0,
2,
2,
0,
0,
0,
2,
2,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02095678
|
12:25:chronic_disease,
|
Late stage renal failure with estimated glomerular filtration rate (eGFR)
| 1
|
[
"Late",
"stage",
"renal",
"failure",
"with",
"estimated",
"glomerular",
"filtration",
"rate",
"(",
"eGFR",
")"
] |
[
0,
0,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02401074
|
1:19:chronic_disease
|
autoimmune disease
| 1
|
[
"autoimmune",
"disease"
] |
[
2,
2
] |
NCT01822522
|
26:40:chronic_disease,44:63:chronic_disease,,109:118:treatment
|
Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment
| 1
|
[
"Concurrent",
"uncompensated",
"hypothyroidism",
"or",
"thyroid",
"dysfunction",
"within",
"7",
"days",
"before",
"the",
"first",
"dose",
"of",
"study",
"treatment"
] |
[
0,
0,
2,
0,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1
] |
NCT01128816
|
186:203:chronic_disease
|
Any other medical, social, or geographical factor, which would make it unlikely that the patient will comply with the study procedures (e.g. alcohol abuse, lack of permanent residence, severe depression, disorientation, distant location, or history of non-compliance)
| 1
|
[
"Any",
"other",
"medical",
",",
"social",
",",
"or",
"geographical",
"factor",
",",
"which",
"would",
"make",
"it",
"unlikely",
"that",
"the",
"patient",
"will",
"comply",
"with",
"the",
"study",
"procedures",
"(",
"e.g",
".",
"alcohol",
"abuse",
",",
"lack",
"of",
"permanent",
"residence",
",",
"severe",
"depression",
",",
"disorientation",
",",
"distant",
"location",
",",
"or",
"history",
"of",
"non-compliance",
")"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02793921
|
5:26:treatment
|
Any breast cancer surgery complications
| 1
|
[
"Any",
"breast",
"cancer",
"surgery",
"complications"
] |
[
0,
1,
1,
1,
0
] |
NCT02509507
|
58:60:cancer,62:65:cancer,67:70:cancer,72:80:cancer,82:87:cancer,92:95:cancer,101:117:cancer,121:124:cancer
|
They must have histologically or cytologically confirmed BC, CRC, GEC, melanoma, NSCLC, or RCC with liver metastases or HCC
| 1
|
[
"They",
"must",
"have",
"histologically",
"or",
"cytologically",
"confirmed",
"BC",
",",
"CRC",
",",
"GEC",
",",
"melanoma",
",",
"NSCLC",
",",
"or",
"RCC",
"with",
"liver",
"metastases",
"or",
"HCC"
] |
[
0,
0,
0,
0,
0,
0,
0,
3,
0,
3,
0,
3,
0,
3,
0,
3,
0,
0,
3,
0,
3,
3,
0,
3
] |
NCT02335905
|
,,153:162:treatment,
|
Female subjects who have reached menarche and are sexually active must be willing to practice sexual abstinence or dual methods of birth control during treatment and for at least 28 days after the last dose of any study drug
| 1
|
[
"Female",
"subjects",
"who",
"have",
"reached",
"menarche",
"and",
"are",
"sexually",
"active",
"must",
"be",
"willing",
"to",
"practice",
"sexual",
"abstinence",
"or",
"dual",
"methods",
"of",
"birth",
"control",
"during",
"treatment",
"and",
"for",
"at",
"least",
"28",
"days",
"after",
"the",
"last",
"dose",
"of",
"any",
"study",
"drug"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT00862433
|
,,51:59:chronic_disease
|
Nonobese (BMI less than or equal to 29.9) without diabetes
| 1
|
[
"Nonobese",
"(",
"BMI",
"less",
"than",
"or",
"equal",
"to",
"29.9",
")",
"without",
"diabetes"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
2
] |
NCT03084640
|
35:48:treatment,
|
who have had SD must have been on pembrolizumab for at least 12 weeks
| 1
|
[
"who",
"have",
"had",
"SD",
"must",
"have",
"been",
"on",
"pembrolizumab",
"for",
"at",
"least",
"12",
"weeks"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0
] |
NCT01851369
|
30:47:cancer,59:75:chronic_disease,118:131:treatment,152:180:treatment
|
Phase II only: patients with colorectal cancer with known MSI-high disease who have not previously been treated with immunotherapy or who have refused treatment with immunotherapy
| 1
|
[
"Phase",
"II",
"only",
":",
"patients",
"with",
"colorectal",
"cancer",
"with",
"known",
"MSI-high",
"disease",
"who",
"have",
"not",
"previously",
"been",
"treated",
"with",
"immunotherapy",
"or",
"who",
"have",
"refused",
"treatment",
"with",
"immunotherapy"
] |
[
0,
0,
0,
0,
0,
0,
3,
3,
0,
0,
2,
2,
0,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
1,
1,
1
] |
NCT03136029
|
1:7:chronic_disease,,,20:46:chronic_disease,,
|
Anemia (Hgb<9) and Severe Renal Insufficiency (individuals with creatinine clearance <30 by the Cockcroft-Gault formula)
| 1
|
[
"Anemia",
"(",
"Hgb",
"<",
"9",
")",
"and",
"Severe",
"Renal",
"Insufficiency",
"(",
"individuals",
"with",
"creatinine",
"clearance",
"<",
"30",
"by",
"the",
"Cockcroft-Gault",
"formula",
")"
] |
[
2,
0,
0,
0,
0,
0,
0,
2,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT01614197
|
12:26:treatment,
|
A positive fungal culture within 30 days
| 1
|
[
"A",
"positive",
"fungal",
"culture",
"within",
"30",
"days"
] |
[
0,
0,
1,
1,
0,
0,
0
] |
NCT02219581
|
17:24:treatment
|
Current chronic steroid use
| 1
|
[
"Current",
"chronic",
"steroid",
"use"
] |
[
0,
0,
1,
0
] |
NCT01465100
|
20:30:cancer
|
Subject has active malignancy
| 1
|
[
"Subject",
"has",
"active",
"malignancy"
] |
[
0,
0,
0,
3
] |
NCT02323880
|
30:63:treatment
|
Patients who have received a prior solid organ transplantation
| 1
|
[
"Patients",
"who",
"have",
"received",
"a",
"prior",
"solid",
"organ",
"transplantation"
] |
[
0,
0,
0,
0,
0,
1,
1,
1,
1
] |
NCT02400255
|
,,102:114:treatment,
|
Women of childbearing potential is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months
| 1
|
[
"Women",
"of",
"childbearing",
"potential",
"is",
"defined",
"as",
"a",
"sexually",
"active",
"mature",
"woman",
"who",
"has",
"not",
"undergone",
"a",
"hysterectomy",
"or",
"who",
"has",
"had",
"menses",
"at",
"any",
"time",
"in",
"the",
"preceding",
"24",
"consecutive",
"months"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02227199
|
54:66:treatment
|
Patients must be anticipated to complete 2 cycles of chemotherapy
| 1
|
[
"Patients",
"must",
"be",
"anticipated",
"to",
"complete",
"2",
"cycles",
"of",
"chemotherapy"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
1
] |
NCT00720785
|
,30:53:treatment
|
At least 2 weeks since prior palliative radiotherapy
| 1
|
[
"At",
"least",
"2",
"weeks",
"since",
"prior",
"palliative",
"radiotherapy"
] |
[
0,
0,
0,
0,
0,
0,
1,
1
] |
NCT02370095
|
15:26:treatment
|
Patient has a tracheotomy
| 1
|
[
"Patient",
"has",
"a",
"tracheotomy"
] |
[
0,
0,
0,
1
] |
NCT02833207
|
1:47:treatment
|
non-steroidal anti-inflammatory drugs (NSAIDs)
| 1
|
[
"non-steroidal",
"anti-inflammatory",
"drugs",
"(",
"NSAIDs",
")"
] |
[
1,
1,
1,
1,
0,
0
] |
NCT02412540
|
8:19:treatment,35:46:chronic_disease,,92:116:treatment,118:130:treatment,132:149:treatment,151:164:treatment
|
use of medications known to cause fatty liver for > 2 consecutive weeks in past year (i.e. systemic glucocorticoids, tetracycline, anabolic steroids, valproic acid)
| 1
|
[
"use",
"of",
"medications",
"known",
"to",
"cause",
"fatty",
"liver",
"for",
">",
"2",
"consecutive",
"weeks",
"in",
"past",
"year",
"(",
"i.e",
".",
"systemic",
"glucocorticoids",
",",
"tetracycline",
",",
"anabolic",
"steroids",
",",
"valproic",
"acid",
")"
] |
[
0,
0,
1,
0,
0,
0,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
1,
0,
1,
0,
1,
1,
0,
1,
1,
0
] |
NCT02319369
|
1:39:treatment
|
Prior treatment with an MDM2 inhibitor
| 1
|
[
"Prior",
"treatment",
"with",
"an",
"MDM2",
"inhibitor"
] |
[
1,
1,
1,
1,
1,
1
] |
NCT02403193
|
21:33:treatment
|
history of complete hysterectomy
| 1
|
[
"history",
"of",
"complete",
"hysterectomy"
] |
[
0,
0,
0,
1
] |
NCT02165007
|
28:37:chronic_disease,39:44:chronic_disease,48:65:chronic_disease,90:99:treatment,
|
Patients with uncontrolled bacterial, viral or fungal infections (undergoing appropriate treatment and with progression of clinical symptoms) within 1 month prior to conditioning
| 1
|
[
"Patients",
"with",
"uncontrolled",
"bacterial",
",",
"viral",
"or",
"fungal",
"infections",
"(",
"undergoing",
"appropriate",
"treatment",
"and",
"with",
"progression",
"of",
"clinical",
"symptoms",
")",
"within",
"1",
"month",
"prior",
"to",
"conditioning"
] |
[
0,
0,
0,
2,
0,
2,
0,
2,
2,
0,
0,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT01720836
|
,,59:68:treatment
|
Subjects must be within 4 to 12 weeks of standard of care treatment for their particular stage of disease
| 1
|
[
"Subjects",
"must",
"be",
"within",
"4",
"to",
"12",
"weeks",
"of",
"standard",
"of",
"care",
"treatment",
"for",
"their",
"particular",
"stage",
"of",
"disease"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0,
0
] |
NCT02152995
|
,,,182:192:treatment
|
men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of trametinib administration
| 1
|
[
"men",
"treated",
"or",
"enrolled",
"on",
"this",
"protocol",
"must",
"also",
"agree",
"to",
"use",
"adequate",
"contraception",
"prior",
"to",
"the",
"study",
",",
"for",
"the",
"duration",
"of",
"study",
"participation",
",",
"and",
"4",
"months",
"after",
"completion",
"of",
"trametinib",
"administration"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0
] |
NCT02293057
|
56:65:treatment
|
observable cognitive or developmental delays or active psychosis that would interfere with completing consent, assessment or intervention
| 1
|
[
"observable",
"cognitive",
"or",
"developmental",
"delays",
"or",
"active",
"psychosis",
"that",
"would",
"interfere",
"with",
"completing",
"consent",
",",
"assessment",
"or",
"intervention"
] |
[
0,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT00186927
|
22:29:treatment
|
prior to evidence of vaccine clearance
| 1
|
[
"prior",
"to",
"evidence",
"of",
"vaccine",
"clearance"
] |
[
0,
0,
0,
0,
1,
0
] |
NCT01954316
|
,,,194:204:treatment
|
Women and men of child producing potential must agree to use highly effective means of contraception during study participation, and for at least 30 days after the last administration of study medication
| 1
|
[
"Women",
"and",
"men",
"of",
"child",
"producing",
"potential",
"must",
"agree",
"to",
"use",
"highly",
"effective",
"means",
"of",
"contraception",
"during",
"study",
"participation",
",",
"and",
"for",
"at",
"least",
"30",
"days",
"after",
"the",
"last",
"administration",
"of",
"study",
"medication"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1
] |
NCT02315196
|
,,,,,,205:214:treatment,
|
Patients with reproductive potential must use an adequate contraceptive method (e.g. abstinence, intrauterine device, oral contraceptives, barrier device with spermicide or surgical sterilization) during treatment and for three months after completing treatment
| 1
|
[
"Patients",
"with",
"reproductive",
"potential",
"must",
"use",
"an",
"adequate",
"contraceptive",
"method",
"(",
"e.g",
".",
"abstinence",
",",
"intrauterine",
"device",
",",
"oral",
"contraceptives",
",",
"barrier",
"device",
"with",
"spermicide",
"or",
"surgical",
"sterilization",
")",
"during",
"treatment",
"and",
"for",
"three",
"months",
"after",
"completing",
"treatment"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0,
0,
0
] |
NCT00716066
|
16:50:chronic_disease
|
Concordant for autoimmune neurological disease(s) as determined by neurological evaluation
| 1
|
[
"Concordant",
"for",
"autoimmune",
"neurological",
"disease",
"(",
"s",
")",
"as",
"determined",
"by",
"neurological",
"evaluation"
] |
[
0,
0,
2,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT00788164
|
1:16:chronic_disease
|
Unstable angina
| 1
|
[
"Unstable",
"angina"
] |
[
2,
2
] |
NCT02467478
|
1:29:chronic_disease,,
|
Chronic Kidney disease (CKD) Stages 1-3
| 1
|
[
"Chronic",
"Kidney",
"disease",
"(",
"CKD",
")",
"Stages",
"1-3"
] |
[
2,
2,
2,
2,
0,
0,
0,
0
] |
NCT02535312
|
77:93:chronic_disease,107:131:chronic_disease,133:157:chronic_disease,159:177:chronic_disease,182:219:chronic_disease
|
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
| 1
|
[
"Uncontrolled",
"intercurrent",
"illness",
"including",
",",
"but",
"not",
"limited",
"to",
",",
"ongoing",
"or",
"active",
"infection",
",",
"symptomatic",
"congestive",
"heart",
"failure",
",",
"unstable",
"angina",
"pectoris",
",",
"cardiac",
"arrhythmia",
",",
"or",
"psychiatric",
"illness/social",
"situations",
"that",
"would",
"limit",
"compliance",
"with",
"study",
"requirements"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
2,
2,
0,
0,
2,
2,
2,
0,
2,
2,
2,
0,
2,
2,
0,
0,
2,
2,
2,
0,
0,
0,
0,
0,
0,
0
] |
NCT03153410
|
69:92:treatment,
|
Currently is participating or has participated in a study using any investigational therapy within the past 28 days or is currently using an investigational device
| 1
|
[
"Currently",
"is",
"participating",
"or",
"has",
"participated",
"in",
"a",
"study",
"using",
"any",
"investigational",
"therapy",
"within",
"the",
"past",
"28",
"days",
"or",
"is",
"currently",
"using",
"an",
"investigational",
"device"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02835729
|
10:19:treatment
|
Previous allo-HSCT of any kind
| 1
|
[
"Previous",
"allo-HSCT",
"of",
"any",
"kind"
] |
[
0,
1,
0,
0,
0
] |
NCT00501826
|
36:48:treatment
|
failure to one induction course of chemotherapy are eligible
| 1
|
[
"failure",
"to",
"one",
"induction",
"course",
"of",
"chemotherapy",
"are",
"eligible"
] |
[
0,
0,
0,
0,
0,
0,
1,
0,
0
] |
NCT02492867
|
37:49:treatment
|
Patients cannot tolerate concurrent chemotherapy
| 1
|
[
"Patients",
"can",
"not",
"tolerate",
"concurrent",
"chemotherapy"
] |
[
0,
0,
0,
0,
0,
1
] |
NCT03048448
|
8:22:treatment,63:89:treatment,114:118:treatment,120:127:treatment,133:137:treatment,168:178:treatment,180:189:treatment,191:204:treatment,210:218:treatment
|
Use of co-medications that may impact QAW039 exposure such as broad range UGT inhibitors or strong inhibitors of OAT3, OATP1B3, and P-gp, including but not limited to probenecid, ritonavir, valproic acid, and rifampin
| 1
|
[
"Use",
"of",
"co-medications",
"that",
"may",
"impact",
"QAW039",
"exposure",
"such",
"as",
"broad",
"range",
"UGT",
"inhibitors",
"or",
"strong",
"inhibitors",
"of",
"OAT3",
",",
"OATP1B3",
",",
"and",
"P-gp",
",",
"including",
"but",
"not",
"limited",
"to",
"probenecid",
",",
"ritonavir",
",",
"valproic",
"acid",
",",
"and",
"rifampin"
] |
[
0,
0,
1,
0,
0,
0,
0,
0,
0,
0,
1,
1,
1,
1,
0,
0,
0,
0,
1,
0,
1,
0,
0,
1,
0,
0,
0,
0,
0,
0,
1,
0,
1,
0,
1,
1,
0,
0,
1
] |
NCT01312857
|
18:28:cancer
|
History of other malignancy
| 1
|
[
"History",
"of",
"other",
"malignancy"
] |
[
0,
0,
0,
3
] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.